Aduhelm™ (aducanumab) – New drug approval
On June 7, 2021, the FDA announced the controversial approval of Biogen’s Aduhelm (aducanumab), for the treatment of Alzheimer’s disease.
We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.
On June 7, 2021, the FDA announced the controversial approval of Biogen’s Aduhelm (aducanumab), for the treatment of Alzheimer’s disease.